Citigroup raised the price target for the Crinetics Pharmaceuticals Inc (NASDAQ:CRNX) stock to “a Buy”. The rating was released on March 06, 2024, according to finviz. The research report from Jefferies has initiated the stock to Hold, with a price target set at $35. The stock was resumed by JP Morgan, who disclosed in a research note on November 20, 2023, to Overweight and set the price objective to $35. In their research brief published October 24, 2023, Cantor Fitzgerald analysts resumed the Crinetics Pharmaceuticals Inc stock to Overweight with a price target of $50.
The latest trade, Performances and Moving Averages give us the following Picture
The firm’s stock price fluctuated 1.68% within the last five trades and -0.16% within the last 30 trades, which was a significant change from the beginning of this year. Despite the fact that the share price increased 49.90% in the last 6 months and 17.58% was added to its value over the previous 3 months. CRNX stock is trading at a margin of -2.23%, 4.33% and 40.62% apart from the 20-Day, 50-Day and 200-Day Simple Moving Average prices.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
As of the close of trading, CRNX deals in the Healthcare domain. The stock is trading -10.81 percent below its 52-week high and 180.58 percent above its 52-week low. For example, looking both at the price and the high and low measurements of 52 weeks will give you a clearer picture of the direction the price is heading. The firm’s Weighted Alpha is 48.68. A positive weighted alpha indicates the firm has done well over the course of the year, whereas one below 0 indicates that the firm has done poorly.
What Does Crinetics Pharmaceuticals Inc’s Profitability and Valuation Ratios Tell Us About the Stock?
With regard to the profitability of the company, the operating margin is currently at 0.00 percent and the company has reported a gross margin of -105.50 percent. The profit margin, also known as the revenue ratio or gross profit ratio, is an efficiency figure used to estimate the business’s profitability by comparing net income and sales. The higher the number, the more profits are generated for the company and vice versa.
The stock’s market cap achieved a total value of $3.45 billion as of the last trading session. Market capitalization is the total value of all outstanding shares of a corporation and it is used to measure a company’s market value. The firm managed a Price-to-Book ratio of 5.59, which equates the market value of a stock with its book value.
Is Insider Trading a Real Thing?
Almost all investors and traders prefer to invest in shares controlled by the management of a corporation as a management company will be more likely to run the business itself and to never conduct things against the management’s desires and will always try to do what is best for their shareholders. Currently, 7.45 percent of Crinetics Pharmaceuticals Inc shares are owned by insiders, and 89.35 percent are held by financial institutions. Pizzuti Dana, the Chief Med and Dev Officer at Crinetics Pharmaceuticals Inc (CRNX) has sold 14,375 shares of firm on Apr 15 ’24 at a price of $44.47 against the total amount of $0.64 million. In another inside trade, Struthers Richard Scott, President & CEO of Crinetics Pharmaceuticals Inc (NASDAQ:CRNX) sold 40,951 shares of the firm on Apr 04 ’24 for a total worth of $2.01 million at a price of $49.17. An inside trade which took place on Mar 28 ’24, Director of Crinetics Pharmaceuticals Inc Okey Stephanie sold 17,500 shares of firm against total price of $0.81 million at the cost of $46.38 per share.
